ERBC (ex CERB) has acquired RTC

December 2019 — The European Research Biology Center (ERBC) has acquired the Research Toxicology Center (RTC).

ERBC provides healthcare and chemical professionals a comprehensive range of experimental capabilities and services, from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, and also benefiting from a world-class academic and private network.

RTC is a fully fledged contract research laboratory located near Rome, Italy, with a track record spanning more than four decades. RTC collaborates with a large range of industrial clients including the pharmaceutical, biotech, chemical, agro-chemical and biocide industries.

Our role in the transaction

Oaklins' team in France advised the buyer in this transaction.

Service

M&A buy-side

Parties

“With the help of Oaklins, we are thrilled to join forces and offer a critical mass of credible and efficient alternative to the big CROs. We are proud to be a unique European player in the field. Our partnerships with the pharma, other CROs and independent experts play a key role in driving improvements in the pharmaceutical and chemical industries, delivering better data to regulators as well as improved value to study sponsors. Oaklins' team gave us fantastic support in a complex transaction.”

Serge Richard

CEO, ERBC

Talk to the deal team

Thibaut de Monclin

Managing Partner

Paris, France
Oaklins France

View profile Get in touch

Related deals

Cibus has acquired Aweta from Standard Investment

Private Equity | Agriculture | Industrial Machinery & Components

Cibus has acquired Aweta from Standard Investment

Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.

Learn more

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Healthcare

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.

Learn more

GroGlass has been acquired by Apogee Enterprises

Private Equity | Other Industries

GroGlass has been acquired by Apogee Enterprises

Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.

Learn more